CR9102A - Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia - Google Patents

Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia

Info

Publication number
CR9102A
CR9102A CR9102A CR9102A CR9102A CR 9102 A CR9102 A CR 9102A CR 9102 A CR9102 A CR 9102A CR 9102 A CR9102 A CR 9102A CR 9102 A CR9102 A CR 9102A
Authority
CR
Costa Rica
Prior art keywords
reductase
hmg
inhibitors
dihidroxi
lipidemia
Prior art date
Application number
CR9102A
Other languages
English (en)
Inventor
Choi Chulho
H Hutchings Richard
A Ptefferkon Jeffrey
Merritt Bowles Daniel
Keun Chan Park William
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708411&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR9102A publication Critical patent/CR9102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen nuevos compuestos y composiciones farmaceuticas utiles como agentes hipocolesterolemicos e hipolipidemicos. Mas especificamente, se describen potentes inhibidores de la enzima 3- hidroxi-3-metilglutaril- coenzima A reductasa ("hmg CoA reductasa").Se describen tambien procedimientos de uso de tales compuestos y composiciones para tratar sujetos, incluyendo seres humanos, que sufren hiperlipidemia, hipercolesterolemia, hipertrigliceridemia, aterosclerosis, enfermedad de alzheimer, hipetrofia prostatica benigna ( HPB), diabetes y osteoporosis
CR9102A 2004-11-23 2007-05-03 Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia CR9102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63048104P 2004-11-23 2004-11-23

Publications (1)

Publication Number Publication Date
CR9102A true CR9102A (es) 2007-05-30

Family

ID=35708411

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9102A CR9102A (es) 2004-11-23 2007-05-03 Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia

Country Status (25)

Country Link
US (2) US7446121B2 (es)
EP (1) EP1819681B1 (es)
JP (1) JP2008520642A (es)
KR (1) KR20070084455A (es)
AP (1) AP2007003979A0 (es)
AR (1) AR052244A1 (es)
AT (1) ATE439347T1 (es)
AU (1) AU2005308575A1 (es)
BR (1) BRPI0518300A2 (es)
CA (1) CA2590533C (es)
CR (1) CR9102A (es)
DE (1) DE602005016009D1 (es)
EA (1) EA200700875A1 (es)
ES (1) ES2328384T3 (es)
GT (1) GT200500338A (es)
IL (1) IL182569A0 (es)
MA (1) MA30108B1 (es)
MX (1) MX2007005137A (es)
NL (1) NL1030487C2 (es)
PA (1) PA8653401A1 (es)
PE (1) PE20061057A1 (es)
TN (1) TNSN07202A1 (es)
TW (1) TW200626556A (es)
UY (1) UY29220A1 (es)
WO (1) WO2006056845A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
WO2008059372A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt
CA2815114A1 (en) * 2010-10-21 2012-04-26 Juergen Benting 1-(heterocyclic carbonyl) piperidines
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9919939B2 (en) 2011-12-06 2018-03-20 Delta Faucet Company Ozone distribution in a faucet
US11458214B2 (en) 2015-12-21 2022-10-04 Delta Faucet Company Fluid delivery system including a disinfectant device
US10988462B2 (en) * 2018-04-04 2021-04-27 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CN114425329B (zh) * 2022-03-10 2024-04-19 西安凯立新材料股份有限公司 孕烯醇酮醋酸酯合成用催化剂及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE637389A (es) 1962-09-13
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
BE795735A (fr) 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS5953920B2 (ja) 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS559058A (en) 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ES8207217A1 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
EP0056194B1 (en) 1981-01-05 1984-09-12 Takeda Chemical Industries, Ltd. N-substituted pseudo-aminosugars, their production and use
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK520784A (da) 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
DE3582674D1 (de) 1984-06-22 1991-05-29 Sandoz Ag Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
US4631286A (en) 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4634765A (en) 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
DE3836675A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
DE3918364A1 (de) 1989-06-06 1990-12-13 Hoechst Ag 3-desmethyl-2-methyl-mevalonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
JPH054943A (ja) 1990-08-30 1993-01-14 Sagami Chem Res Center 光学活性β，δ−ジケト酸エステル及びその還元体
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
EP0796864A2 (en) 1992-06-26 1997-09-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
JP2789134B2 (ja) 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
DE69616808T2 (de) 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
JPH09173638A (ja) * 1995-12-25 1997-07-08 Hudson Soft Co Ltd 相対時間による派生シナリオ起動方法
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
JPH10310578A (ja) * 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
EP1048653B1 (en) 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
PA8471201A1 (es) 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE69913138T2 (de) 1999-03-31 2004-08-26 Eisai Co., Ltd. Stabilisierte zusammensetzung mit nootropen wirkstoffen
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6458852B1 (en) 1999-09-23 2002-10-01 G.D. Searle & Co. Use of substituted N, N-bis-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
US6544974B2 (en) 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030171377A1 (en) 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CA2507465C (en) 2002-11-26 2009-04-28 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
BR0317593A (pt) 2002-12-20 2005-11-22 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
JP2007532653A (ja) * 2004-04-16 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 新規なイミダゾール類
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia

Also Published As

Publication number Publication date
MX2007005137A (es) 2007-06-22
ES2328384T3 (es) 2009-11-12
NL1030487A1 (nl) 2006-05-24
GT200500338A (es) 2006-06-22
US20090170852A1 (en) 2009-07-02
AR052244A1 (es) 2007-03-07
WO2006056845A1 (en) 2006-06-01
ATE439347T1 (de) 2009-08-15
US7446121B2 (en) 2008-11-04
AP2007003979A0 (en) 2007-06-30
BRPI0518300A2 (pt) 2008-11-11
PE20061057A1 (es) 2006-11-09
NL1030487C2 (nl) 2007-01-08
DE602005016009D1 (de) 2009-09-24
IL182569A0 (en) 2007-07-24
TW200626556A (en) 2006-08-01
US20060111422A1 (en) 2006-05-25
TNSN07202A1 (fr) 2008-11-21
EA200700875A1 (ru) 2007-12-28
CA2590533C (en) 2010-09-07
CA2590533A1 (en) 2006-06-01
AU2005308575A1 (en) 2006-06-01
JP2008520642A (ja) 2008-06-19
MA30108B1 (fr) 2009-01-02
KR20070084455A (ko) 2007-08-24
EP1819681A1 (en) 2007-08-22
EP1819681B1 (en) 2009-08-12
UY29220A1 (es) 2006-06-30
PA8653401A1 (es) 2006-09-08

Similar Documents

Publication Publication Date Title
CR9102A (es) Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia
CL2004000985A1 (es) Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
CL2007001873A1 (es) Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
CL2008000762A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
TW200745052A (en) Thyroid hormone receptor agonists
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
PA8462301A1 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa
UY26776A1 (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos.
WO2006118948A3 (en) Therapeutic compositions
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
CR9903A (es) Compuestos antihipercolesterolemicos
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
ECSP056193A (es) Derivados sustituidos del pirrol
BRPI0507998A (pt) uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia
BR0109838A (pt) Metabólitos de agonista/antagonista de estrogênio
BRPI0519152A2 (pt) composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
AR044774A1 (es) Composiciones farmaceuticas de atorvastatina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)